Conatus Initiates Phase 2b Trial of Emricasan in Acute-on-Chronic Liver ... HispanicBusiness.com The morbidity and mortality of the patient population Conatus plans to study is high, and up to 45% of the patients may die, develop multi-organ failure, or require a liver transplant as a result of the decompensation episode within 28 days of ... Conatus Pharmaceuticals Initiates Phase 2b Trial of Emricasan in Acute-on ... |
